Best Practices in Immunotherapy Symptom Management and Patient Education

Nurses play a critical role in the recognition and management of irAEs. Current management strategies are primarily based on clinical experience from high-volume centers, and many nurses have limited experience managing immunotherapy-related toxicity. Clinician education and training are needed to manage the needs of the growing patient population treated with these agents. The NCCN Guidelines provide recommendations for managing irAEs as well as guiding principles for immunosuppression in the setting of toxicity. Importantly, these guidelines also provide guidance for multidisciplinary teams regarding clinician and patient education. Knowledge gained in this arena will support timely detection and management of potentially life-threatening adverse events.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:    

  • Understand the scope and presentation of immunotherapy-related toxicity 
  • Assess patients on immunotherapy for potential irAEs
  • Apply the NCCN Guidelines for managing irAEs
Additional information
Supporters: 

This activity is supported by an educational grant from:

  • AstraZeneca
  • Genentech
  • Pfizer
  • Taiho Oncology, Inc.

This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 0.84 ANCC contact hours
  • 0.84 Participation
Course opens: 
05/15/2019
Course expires: 
05/15/2020
Cost:
$0.00

Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP
Yale Cancer Center/Smilow Cancer Hospital      

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers 

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Bristol-Myers Squibb Company: Product/Speakers Bureau
Genentech, Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (Employed by NCCN until 8/10/18); Wui-Jin Koh, MD; Joan S. McClure, MS (Employed by NCCN until 8/1/18); Lisa Perfidio, MS; Sarah Sinclair; Kathy Ann Smith, CHCP; Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Jillian Scavone, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of  0.84 contact hours.

Available Credit

  • 0.84 ANCC contact hours
  • 0.84 Participation

Accreditation Period

Course opens: 
05/15/2019
Course expires: 
05/15/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: